5.8714
price up icon1.23%   0.0714
after-market After Hours: 5.87 -0.0014 -0.02%
loading
Tenax Therapeutics Inc stock is traded at $5.8714, with a volume of 5,752. It is up +1.23% in the last 24 hours and down -9.53% over the past month. Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$5.80
Open:
$5.85
24h Volume:
5,752
Relative Volume:
0.16
Market Cap:
$21.32M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3491
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+14.23%
1M Performance:
-9.53%
6M Performance:
+20.56%
1Y Performance:
+68.72%
1-Day Range:
Value
$5.6396
$5.9976
1-Week Range:
Value
$4.63
$5.9976
52-Week Range:
Value
$2.77
$7.89

Tenax Therapeutics Inc Stock (TENX) Company Profile

Name
Name
Tenax Therapeutics Inc
Name
Phone
919-855-2100
Name
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Name
Employee
6
Name
Twitter
@TenaxThera
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
TENX's Discussions on Twitter

Compare TENX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TENX
Tenax Therapeutics Inc
5.8714 21.32M 0 -14.56M -12.46M -16.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Initiated Leerink Partners Outperform
Oct-14-24 Initiated Guggenheim Buy
Sep-30-24 Initiated William Blair Outperform
May-18-17 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14 Initiated MLV & Co Buy
Nov-18-14 Initiated WallachBeth Buy
View All

Tenax Therapeutics Inc Stock (TENX) Latest News

pulisher
Apr 25, 2025

Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN

Apr 25, 2025
pulisher
Apr 25, 2025

SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow

Apr 25, 2025
pulisher
Apr 25, 2025

Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 24 - StreetInsider

Apr 25, 2025
pulisher
Apr 24, 2025

Tenax Therapeutics Advances Cardiopulmonary Therapies - TipRanks

Apr 24, 2025
pulisher
Apr 22, 2025

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - The Globe and Mail

Apr 22, 2025
pulisher
Apr 22, 2025

Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Oxygen Biotherapeutics, Inc. : Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast - marketscreener.com

Apr 21, 2025
pulisher
Apr 17, 2025

Teanx Therapeutics plans secondary offering - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Tenax Therapeutics (TENX) Files Prospectus for Stock Resale - GuruFocus

Apr 16, 2025
pulisher
Apr 14, 2025

Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World

Apr 14, 2025
pulisher
Mar 31, 2025

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Q1 Earnings Estimate for TENX Issued By William Blair - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Research Analysts Set Expectations for TENX Q1 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

When (TENX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider

Mar 25, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph

Mar 25, 2025
pulisher
Mar 25, 2025

Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 21, 2025

Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.

Mar 19, 2025
pulisher
Mar 11, 2025

Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

(TENX) Proactive Strategies - news.stocktradersdaily.com

Mar 06, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics announces $25M private placement - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics secures $25 million in private placement - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News

Mar 05, 2025
pulisher
Mar 03, 2025

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Can Tenax Therapeutics' Conference Appearance Signal New Cardiovascular Treatment Progress? - StockTitan

Mar 03, 2025
pulisher
Feb 26, 2025

Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 - ACCESS Newswire

Feb 26, 2025

Tenax Therapeutics Inc Stock (TENX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):